Fatigue: A Neurological Symptom Worth Investigating

Normal tiredness follows exertion and resolves with rest. Neurological fatigue persists despite adequate sleep, worsens with cognitive effort rather than physical activity, and often carries additional features: difficulty concentrating, word-finding problems, slowed processing speed, or a feeling that thinking itself requires unusual effort. If you are sleeping seven to eight hours and waking unrefreshed, or if rest does not restore your baseline, the fatigue likely has a physiological cause worth investigating. Duration matters as well. Fatigue lasting more than four to six weeks that cannot be explained by an obvious life circumstance warrants evaluation.

Our workup is designed to identify the specific mechanism driving the fatigue rather than simply confirming that fatigue is present. We begin with a detailed clinical history and neurological examination. Laboratory testing includes comprehensive metabolic panels, thyroid function with free T3 and free T4, inflammatory markers including C-reactive protein and erythrocyte sedimentation rate, NAD+ levels, vitamin B12 with methylmalonic acid, folate, ferritin, fasting insulin, HbA1c, cortisol, and in selected cases autoimmune panels and mitochondrial function markers such as lactate-to-pyruvate ratio and organic acid profiles. Neuroimaging and cognitive testing are added when the clinical picture suggests a central nervous system process.

No. Chronic fatigue syndrome, now called myalgic encephalomyelitis/chronic fatigue syndrome or ME/CFS, is a specific diagnosis defined by post-exertional malaise, unrefreshing sleep, and either cognitive impairment or orthostatic intolerance lasting at least six months. It is one possible explanation for persistent fatigue, but it is not the only one. Many patients referred with a presumptive diagnosis of chronic fatigue syndrome turn out to have an identifiable and treatable cause: thyroid dysfunction, mitochondrial impairment, sleep apnea, or neuroinflammation. Our evaluation is designed to identify those causes first. If the clinical picture meets criteria for ME/CFS, we treat that specifically. We have a dedicated page covering our approach to ME/CFS at neurogenesisproject.com/treatments/mecfs-chronic-fatigue.

Treatment depends entirely on what the evaluation reveals. NAD+ intravenous therapy is central to our approach when mitochondrial dysfunction is identified, because NAD+ is the primary electron carrier in oxidative phosphorylation and its depletion directly impairs cellular energy production. Glutathione IV therapy addresses the oxidative stress that frequently accompanies mitochondrial compromise. Myers' Cocktail IV delivers magnesium, B-complex vitamins, and vitamin C to correct nutritional deficiencies that impair energy metabolism. Beyond infusion therapy, we address sleep architecture, metabolic optimization, hormonal balance, and any identified inflammatory or autoimmune process driving the fatigue.

The initial consultation and neurological examination typically take 60 to 90 minutes. Laboratory results return over the following one to two weeks depending on the complexity of the panel. Neuroimaging, if indicated, can usually be completed within the first week. We schedule a follow-up to review all results and present a treatment plan once the full diagnostic picture is available. For patients traveling to St. Marys, we can often coordinate the consultation, labs, and imaging within a concentrated visit.

Yes, though the approach depends on the nature and severity of the dysfunction. Acquired mitochondrial impairment from metabolic stress, toxic exposures, or chronic inflammation is often reversible when the underlying driver is corrected and the mitochondria are provided with the substrates they need to recover. NAD+ is the most direct intervention because it is the required coenzyme for complexes I through IV of the electron transport chain. Coenzyme Q10, alpha-lipoic acid, and B vitamins serve as additional cofactors. Primary mitochondrial diseases caused by genetic mutations in mitochondrial or nuclear DNA are not curable, but their metabolic consequences can often be mitigated. The first step is determining which type of mitochondrial problem is present.

We evaluate mitochondrial function through blood-based biomarkers including organic acid profiles, lactate-to-pyruvate ratios, coenzyme Q10 levels, and carnitine profiles. We also measure NAD+ levels and markers of oxidative stress including 8-OHdG and F2-isoprostanes. These are available through specialty reference laboratories and provide actionable data about cellular energy production.

Depression-related fatigue tends to be worst in the morning with some improvement as the day progresses, accompanied by anhedonia and mood changes. Neurological fatigue worsens with cognitive or physical exertion and does not correlate with mood predictably. Lab work differentiates them: mitochondrial markers, inflammatory cytokines, and neurotransmitter metabolites produce different patterns. The distinction matters because the treatments are different.

When the fatigue has a metabolic or mitochondrial basis, IV therapies can produce noticeable improvement. NAD+ directly replenishes the central coenzyme in mitochondrial ATP production. The Myers' Cocktail provides magnesium and B vitamins at concentrations that bypass gastrointestinal absorption limitations. Many fatigue patients have impaired gut absorption, which is why oral supplementation has not worked. These therapies are not appropriate for all causes of fatigue, which is why the diagnostic evaluation comes first.